

Radiation Dose Assessments in the NTPR Program

VBDR Meeting: March 7-8, 2007

John H. Stiver, MS, CHP

SAIC





Briefing Outline

- **Radiation Dose Assessment (RDA) Overview**
 - **Hierarchy of Guidance**
 - **Procedural Hierarchy**
 - **NTPR Case Processing Model**
 - **RDA Processing Model**
 - **The Non-Generic RDA**
 - **The Generic RDA (cohort based)**
 - **The Road Ahead**
-
- **Projected Briefing Time: 30 minutes**



Overview

- **Purpose**

- Describe the detailed process for preparing the NTPR RDA Report

- **SOP Status**

- Draft form (November 2006)
- Scheduled for completion in the summer of 2007

- **RDA Reports are prepared for:**

- Japanese-held prisoners of war or occupation forces located near Hiroshima and Nagasaki
- Atmospheric nuclear test participants (1945 – 1962) and non-participants as requested by DVA

- **In response to requests from:**

- DVA, individuals, approved parties



Hierarchy of Guidance

- **Code of Federal Regulations**
 - 32 CFR 218 (DoD - Principal Regulatory Guidance)
 - 38 CFR 3.102 (DVA - Benefit of the doubt)
 - 38 CFR 3.311 (DVA Non-Presumptive) and 38 CFR 3.309 (DVA Presumptive): Not guidance but have significant influence on the program
- **DTRA Policy and Guidance (P&G) Manual**
- **Quality Plan (Describes Quality Management system)**
- **Standard Operating Procedures (SOP) Manual**



Procedural Hierarchy

- **Standard Operating Procedures**
 - Detailed work instructions, activity steps, responsibilities, quality control and quality assurance, record management
- **Standard Methods (SMs) Provide:**
 - Analytical methods, techniques, calculation tools; citations for technical information and scientific basis
- **Operation/Shot-Specific Information Appendices (A – C)**
 - Detailed data on radiation environments
 - Assumptions
 - Numerical parameters
- **Compendium of References (Appendices D-G)**



Standard Operating Procedures


- **Ensure that RDAs:**

- Follow a standard process
- Use consistent methodologies with reproducible results
- **Provide sufficient information for the DVA to make sound compensation decisions (Key)**
- Consider all relevant information, technically sound methods, appropriate assessment of uncertainty
- Produce quality reports: error-free, timely, appropriate level of documentation
- Reflect benefit of the doubt consistent with DTRA policy and guidance, DVA requirements (38 CFR 3.102)



NTPR Case Processing Model

L-3 Titan
09/15/06





Case Processing Model

- **Scenario of Participation and Radiation Exposure (SPARE)**
 - Characterizes the veterans activities in space and time (what they did and when and where they did it)
 - Veteran reviews and comments
- **RDA Report Preparation and Review**



Radiation Dose Assessment

- **RDA Report Definition**
- **RDA Required For Claims not handled through DTRA's Expedited Processing Methods:**
 - Presumptive radiogenic diseases where the claim was filed prior to the disease being designated as presumptive
 - Non-presumptive radiogenic diseases
 - Non-radiogenic diseases
 - ❖ competent scientific or medical evidence that claimed condition is radiogenic

RDA Reports are prepared according to:



RDA Process Flow



Non-Generic RDA

- **Governed by:**
 - SOP RA02, Radiation Dose Assessment for Non-Generic Cases
- **Requires:**
 - Adapted dose assessment tools, new calculation modules
- **Tailored to:**
 - Specific activities, radiation environments
 - Organs, anatomical locations (skin/eye)
- **Quality Assurance Considerations**
- **Greater Potential for Exposure**



Non-Generic RDA

- **Review SPARE and Case File and Confirm Status**
 - Required information available?
 - Identify conflicts, inconsistencies
 - Non-generic status?
 - Collect additional information if needed
- **Requires:**
 - SPARE (preferably reviewed and signed by the veteran)
 - Complete case file



Non-Generic RDA

- **Identify Exposure Scenario and Define Exposure Pathways**
 - **Key step (where you need to get it right!)**
 - **Characterize radiation environment**
 - ❖ Initial radiation
 - ❖ Residual radiation
 - **Identify significant exposure activities**
 - ❖ Temporal and spatial relationship to the radiation environment



Non-Generic RDA

- **Assess Whole-Body External Dose**
 - Basis for skin/eye, internal (surface-deposited sources)
 - **Hierarchy of methods (32 CFR 218)**
 - ❖ Personal dosimetry (film badge) (SM ED01)
 - ❖ Cohort dosimetry
 - ❖ Reconstruction
 - Dosimetry unavailable or unreliable (criteria)



Non-Generic RDA

- **Reconstructed Whole Body Doses**
 - Assumptions and numerical parameters
 - Dose estimates (SM ED02, Appendices A-C)
 - ❖ **Initial gamma, neutron**
 - **Depends on:** Distance, posture, shielding, atmosphere
 - **Based on:** Technical reports, transport codes
 - ❖ **Residual gamma**
 - **Depends on:** temporal/spatial relationship to radiation environment
 - **Based on:** SPARE, technical reports, measurements, historical records



Non-Generic RDA

- **Total External and Upper Bound Doses**
 - **Gamma, neutron** (Film badge plus reconstructions)
 - **Upper bound (SM UA01)**
 - ❖ Identify uncertainties
 - Independent and dependent sources
 - Uncertainty factors (DTRA P&G, NAS 1989)
 - ❖ Combine uncertainties to get total uncertainty increment
 - ❖ Upper Bound = mean plus uncertainty increment



Non-Generic RDA

- **Assess Internal Dose**

- **50-year Committed Equivalent Dose (CED) to organs/tissues**
- **Published DCFs (32 CFR 218)**
 - ❖ Recent ICRP models
 - ❖ Surrogates
- **Pathways**
 - ❖ Inhalation
 - Descending fallout
 - Suspended/resuspended contaminants
 - Atmospheric cloud
 - ❖ Ingestion
 - ❖ Absorption (skin or wound)



Non-Generic RDA

- **Calculate Organ Doses (SM ID01)**
 - Alpha and beta plus gamma separately
 - Each organ and pathway
 - Shot-specific DCFs (FIIDOS)
 - Tabulated values simplify calculations
 - ❖ Rem (CED)/curie
 - ❖ Rem (CED)/rem (FBE)
 - Totals and upper bounds (SM UA01)



Non-Generic RDA

- **Organ Dose – Benefit of Doubt is Ensured by:**
 - Full exposure –descending fallout
 - Ingestion – peak rate of deposition
 - “Maximum dose” DCFs
 - Inventory depletion - radiological decay only
 - High-sided resuspension factors
 - Uncertainty factor of 10 (RBE, models)



Non-Generic RDA

- **Assess Skin Dose**
 - **Beta plus gamma (and neutron)**
 - **Expedited processing (DTRA)**
 - ❖ All except H&N (and others on case by case basis as determined by DTRA)
 - **Principal pathways**
 - ❖ Surface deposited fallout and point sources (SM ED03)
 - ❖ Dermal contamination (SM ED04)



Non-Generic RDA

- **Gamma Doses to the Skin**
 - Same as whole body gamma
- **Beta Doses to the Skin**
 - Assumptions and estimates
 - ❖ Beta to gamma ratios (beta “shine”)
 - ❖ Shielding, posture, geometry
 - ❖ Anatomical location
 - ❖ Direct contamination



Non-Generic RDA

- **Skin Dose Calculations**
 - Surface-deposited (SM ED03)
 - Dermal contamination (SM ED04)
- **Totals and Upper Bounds**
 - Each exposure type and skin location
 - Upper bound (SM UA01)



Non-Generic RDA

- **Assess Eye Lens Dose**
 - **DTRA is considering Expedited Processing for eye lens**
 - **Beta plus gamma (and neutron)**
 - **Principal pathways**
 - ❖ **Surface deposited fallout (SM ED05)**
 - Same approach as for skin dose
 - 3000 μm for eye lens vs. 70 μm for skin
 - ❖ **Dermal contamination (SM ED04)**
 - Eyelid and orbit (ratios of lens to skin dose)
 - **Upper bound (SM UA01)**



Non-Generic RDA

- **Prepare Draft RDA Report**
 - Dose results, scenario, assumptions
- **Internal Quality Reviews**
 - Technical, CHP, Management
 - Tracking form
- **Prepare Final RDA Report**
- **Transmit to Enterprise Manager**



Non-Generic RDA

- **Quality Control and Assurance**
 - Calculation tools and templates
 - Internal review
 - External review (not part of DR Team)
 - Audits
 - Official copies retained by Enterprise Manager



Generic RDA

- **Variant of the Non-Generic RDA**
- **Cohort Approach**
 - Activity scenario (large # participants)
 - Radiation environment (well defined)
- **Standardized:**
 - Assumptions, tools, templates
- **Improved Efficiency**
- **Comprehensive Documentation**



Generic RDA

- **Templates, Tools Available for:**
 - **Hiroshima and Nagasaki**
 - **Oceanic test series**
 - **Nevada Test Site (under development)**
 - **Observers, Maneuver troops**



Generic RDA

- **Calculation Input**

- Arrival and departure
- Time weighted shielding factor (TWSF)
- Dosimetry (evaluate veracity)
- Periods for reconstruction
- Posture, geometric considerations (skin, eye)
- Target organ(s)



Generic RDA

- **Generic RDA Report Templates**
Placeholders for:
 - Target organs, skin cancer locations
 - Response to veteran's comments (SPARE)
 - Parameters, assumptions
 - Personal information
- **QA/QC and Case Processing same as for Non-Generic RDA**



The Road Ahead

- Finalize SOPs, Standard Methods, Appendices
- Develop Library of Technical Basis Documents
- Complete Templates for NTS Operations
- Identify Additional Categories for Possible Expedited Processing or Generic RDA
- Rigorous Uncertainty Analysis
 - Supplant UB Factors with Probabilistic Uncertainty Analysis (Monte Carlo)



Questions?